DUB Inhibitors Market to Witness Strong Expansion Across 7MM by 2040 Driven by the Launch of Novel Therapeutics | DelveInsight [Yahoo! Finance]
Tango Therapeutics, Inc. (TNGX)
Company Research
Source: Yahoo! Finance
The growing prevalence of cancer and neurodegenerative disorders further supports market expansion. Additionally, the launch of emerging therapies such as ISM-3091 (InSilico Medicine), OAT-4828 (Molecure), KSQ-4279 (KSQ Therapeutics/Roche), MTX652 and MTX325 (Mission Therapeutics), and others will propel the market. LAS VEGAS Jan. 28, 2026 /PRNewswire/ -- DelveInsight's DUB Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Heart Failure, Parkinson's Disease, Alzheimer's Disease, Lymphoma, Breast Cancer, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging DUB inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2040, segmented into leading markets (the US, EU
Show less
Read more
Impact Snapshot
Event Time:
TNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNGX alerts
High impacting Tango Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNGX
News
- Tango Therapeutics (TNGX) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TNGX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "holMarketBeat
- Tango Therapeutics' (TNGX) Sees Cautious Analyst Optimism Following Earnings [Yahoo! Finance]Yahoo! Finance
- Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX) [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics (TNGX) had its price target raised by Mizuho from $19.00 to $20.00. They now have an "outperform" rating on the stock.MarketBeat
- Tango Therapeutics (TNGX) had its price target raised by Stifel Nicolaus from $15.00 to $24.00. They now have a "buy" rating on the stock.MarketBeat
TNGX
Earnings
- 3/5/26 - Beat
TNGX
Sec Filings
- 3/9/26 - Form 4
- 3/5/26 - Form 144
- 3/5/26 - Form S-8
- TNGX's page on the SEC website